原文出处:U.S. FDA Grants Fast Track Designation to Asana BioSciences’ Oral Dual JAK-SYK Inhibitor, ASN002, for the Treatment of Atopic Dermatitis 原标题:新型抗炎药!美国FDA授予口服JAK/SYK双效抑制剂ASN002治疗特应性皮炎的快速通道资格
1.Bissonnette, R., Maari, C., Forman, S., et al.The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: Results from a randomized double-blind placebo-controlled studyBr...
ATOPIC dermatitisDRUG side effectsBLOOD proteinsSummary Few medicines are available for the treatment of moderate鈥恡o鈥恠evere atopic eczema. ASN002 is a new oral (taken by mouth) drug being tested that has been shown to reduce the activity of various proteins playing a role in skin ...